nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—Citalopram—ABCB1—peripheral nervous system neoplasm	0.00676	1	CrCbGaD
Escitalopram—ADRA1A—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000157	0.00811	CbGpPWpGaD
Escitalopram—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000154	CcSEcCtD
Escitalopram—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000154	CcSEcCtD
Escitalopram—Constipation—Etoposide—peripheral nervous system neoplasm	0.00015	0.000154	CcSEcCtD
Escitalopram—Pain—Etoposide—peripheral nervous system neoplasm	0.00015	0.000154	CcSEcCtD
Escitalopram—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000154	CcSEcCtD
Escitalopram—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000154	CcSEcCtD
Escitalopram—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000154	CcSEcCtD
Escitalopram—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000153	CcSEcCtD
Escitalopram—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000149	0.000153	CcSEcCtD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000148	0.00766	CbGpPWpGaD
Escitalopram—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000148	0.000152	CcSEcCtD
Escitalopram—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000152	CcSEcCtD
Escitalopram—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000152	CcSEcCtD
Escitalopram—HRH1—IL-4 Signaling Pathway—BIRC5—peripheral nervous system neoplasm	0.000147	0.0076	CbGpPWpGaD
Escitalopram—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000151	CcSEcCtD
Escitalopram—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.00015	CcSEcCtD
Escitalopram—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000146	0.00015	CcSEcCtD
Escitalopram—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000149	CcSEcCtD
Escitalopram—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000149	CcSEcCtD
Escitalopram—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000149	CcSEcCtD
Escitalopram—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000149	CcSEcCtD
Escitalopram—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000145	0.000148	CcSEcCtD
Escitalopram—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000148	CcSEcCtD
Escitalopram—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000144	0.000148	CcSEcCtD
Escitalopram—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000148	CcSEcCtD
Escitalopram—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000147	CcSEcCtD
Escitalopram—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000143	0.000147	CcSEcCtD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000143	0.00739	CbGpPWpGaD
Escitalopram—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000143	0.000147	CcSEcCtD
Escitalopram—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000143	0.000147	CcSEcCtD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000143	0.00737	CbGpPWpGaD
Escitalopram—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000146	CcSEcCtD
Escitalopram—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000146	CcSEcCtD
Escitalopram—SLC6A3—Parkinsons Disease Pathway—CASP3—peripheral nervous system neoplasm	0.000142	0.00735	CbGpPWpGaD
Escitalopram—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000142	0.000145	CcSEcCtD
Escitalopram—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000142	0.000145	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000145	CcSEcCtD
Escitalopram—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000141	0.000145	CcSEcCtD
Escitalopram—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000145	CcSEcCtD
Escitalopram—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000141	0.000145	CcSEcCtD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000141	0.00725	CbGpPWpGaD
Escitalopram—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000144	CcSEcCtD
Escitalopram—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000139	0.000143	CcSEcCtD
Escitalopram—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000143	CcSEcCtD
Escitalopram—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000143	CcSEcCtD
Escitalopram—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000143	CcSEcCtD
Escitalopram—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000142	CcSEcCtD
Escitalopram—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000139	0.000142	CcSEcCtD
Escitalopram—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000139	0.000142	CcSEcCtD
Escitalopram—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000142	CcSEcCtD
Escitalopram—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000142	CcSEcCtD
Escitalopram—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000142	CcSEcCtD
Escitalopram—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000142	CcSEcCtD
Escitalopram—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000141	CcSEcCtD
Escitalopram—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000138	0.000141	CcSEcCtD
Escitalopram—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000137	0.000141	CcSEcCtD
Escitalopram—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000141	CcSEcCtD
Escitalopram—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.00014	CcSEcCtD
Escitalopram—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000137	0.00014	CcSEcCtD
Escitalopram—Rash—Vincristine—peripheral nervous system neoplasm	0.000137	0.00014	CcSEcCtD
Escitalopram—SLC6A2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000136	0.00704	CbGpPWpGaD
Escitalopram—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000136	0.00014	CcSEcCtD
Escitalopram—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000136	0.00014	CcSEcCtD
Escitalopram—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.00014	CcSEcCtD
Escitalopram—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000136	0.00014	CcSEcCtD
Escitalopram—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000139	CcSEcCtD
Escitalopram—Headache—Vincristine—peripheral nervous system neoplasm	0.000136	0.000139	CcSEcCtD
Escitalopram—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000139	CcSEcCtD
Escitalopram—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000138	CcSEcCtD
Escitalopram—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000137	CcSEcCtD
Escitalopram—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000133	0.000137	CcSEcCtD
Escitalopram—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000137	CcSEcCtD
Escitalopram—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000137	CcSEcCtD
Escitalopram—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—peripheral nervous system neoplasm	0.000133	0.00685	CbGpPWpGaD
Escitalopram—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000131	0.000135	CcSEcCtD
Escitalopram—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000134	CcSEcCtD
Escitalopram—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000134	CcSEcCtD
Escitalopram—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000133	CcSEcCtD
Escitalopram—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000129	0.000133	CcSEcCtD
Escitalopram—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000132	CcSEcCtD
Escitalopram—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000132	CcSEcCtD
Escitalopram—Nausea—Vincristine—peripheral nervous system neoplasm	0.000129	0.000132	CcSEcCtD
Escitalopram—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000132	CcSEcCtD
Escitalopram—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000132	CcSEcCtD
Escitalopram—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000132	CcSEcCtD
Escitalopram—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000131	CcSEcCtD
Escitalopram—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000131	CcSEcCtD
Escitalopram—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000131	CcSEcCtD
Escitalopram—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000131	CcSEcCtD
Escitalopram—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.00013	CcSEcCtD
Escitalopram—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.00013	CcSEcCtD
Escitalopram—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000126	0.000129	CcSEcCtD
Escitalopram—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000129	CcSEcCtD
Escitalopram—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000129	CcSEcCtD
Escitalopram—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000129	CcSEcCtD
Escitalopram—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000128	CcSEcCtD
Escitalopram—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000128	CcSEcCtD
Escitalopram—Chills—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000128	CcSEcCtD
Escitalopram—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000124	0.000127	CcSEcCtD
Escitalopram—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000127	CcSEcCtD
Escitalopram—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000127	CcSEcCtD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000122	0.00632	CbGpPWpGaD
Escitalopram—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000126	CcSEcCtD
Escitalopram—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000122	0.000125	CcSEcCtD
Escitalopram—SLC6A4—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000122	0.00628	CbGpPWpGaD
Escitalopram—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000124	CcSEcCtD
Escitalopram—SLC6A4—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000121	0.00625	CbGpPWpGaD
Escitalopram—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000124	CcSEcCtD
Escitalopram—SLC6A3—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000121	0.00624	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000121	0.00624	CbGpPWpGaD
Escitalopram—Rash—Cisplatin—peripheral nervous system neoplasm	0.000121	0.000124	CcSEcCtD
Escitalopram—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000121	0.000124	CcSEcCtD
Escitalopram—Erythema—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000124	CcSEcCtD
Escitalopram—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000124	CcSEcCtD
Escitalopram—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00012	0.000123	CcSEcCtD
Escitalopram—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000123	CcSEcCtD
Escitalopram—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000123	CcSEcCtD
Escitalopram—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000122	CcSEcCtD
Escitalopram—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000122	CcSEcCtD
Escitalopram—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000122	CcSEcCtD
Escitalopram—Tension—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000121	CcSEcCtD
Escitalopram—HRH1—IL-4 Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.000118	0.0061	CbGpPWpGaD
Escitalopram—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000121	CcSEcCtD
Escitalopram—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000117	0.00012	CcSEcCtD
Escitalopram—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000117	0.00012	CcSEcCtD
Escitalopram—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000119	CcSEcCtD
Escitalopram—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000116	0.000119	CcSEcCtD
Escitalopram—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000119	CcSEcCtD
Escitalopram—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000119	CcSEcCtD
Escitalopram—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000119	CcSEcCtD
Escitalopram—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000118	CcSEcCtD
Escitalopram—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000117	CcSEcCtD
Escitalopram—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000114	0.000117	CcSEcCtD
Escitalopram—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000117	CcSEcCtD
Escitalopram—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000116	CcSEcCtD
Escitalopram—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000115	CcSEcCtD
Escitalopram—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000115	CcSEcCtD
Escitalopram—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000112	0.000115	CcSEcCtD
Escitalopram—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000114	CcSEcCtD
Escitalopram—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000114	CcSEcCtD
Escitalopram—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000114	CcSEcCtD
Escitalopram—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000114	CcSEcCtD
Escitalopram—Rash—Etoposide—peripheral nervous system neoplasm	0.000111	0.000114	CcSEcCtD
Escitalopram—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.00011	0.000113	CcSEcCtD
Escitalopram—Headache—Etoposide—peripheral nervous system neoplasm	0.00011	0.000113	CcSEcCtD
Escitalopram—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000113	CcSEcCtD
Escitalopram—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000112	CcSEcCtD
Escitalopram—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000112	CcSEcCtD
Escitalopram—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000112	CcSEcCtD
Escitalopram—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000111	CcSEcCtD
Escitalopram—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000111	CcSEcCtD
Escitalopram—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000111	CcSEcCtD
Escitalopram—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000111	CcSEcCtD
Escitalopram—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000111	CcSEcCtD
Escitalopram—SLC6A4—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000108	0.00556	CbGpPWpGaD
Escitalopram—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.00011	CcSEcCtD
Escitalopram—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000109	CcSEcCtD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000106	0.00547	CbGpPWpGaD
Escitalopram—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000109	CcSEcCtD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000106	0.00546	CbGpPWpGaD
Escitalopram—Cough—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000108	CcSEcCtD
Escitalopram—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000108	CcSEcCtD
Escitalopram—SLC6A2—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000105	0.0054	CbGpPWpGaD
Escitalopram—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000107	CcSEcCtD
Escitalopram—Nausea—Etoposide—peripheral nervous system neoplasm	0.000104	0.000107	CcSEcCtD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000104	0.00537	CbGpPWpGaD
Escitalopram—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000107	CcSEcCtD
Escitalopram—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000106	CcSEcCtD
Escitalopram—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000106	CcSEcCtD
Escitalopram—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000105	CcSEcCtD
Escitalopram—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000105	CcSEcCtD
Escitalopram—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000105	CcSEcCtD
Escitalopram—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000105	CcSEcCtD
Escitalopram—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000105	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000105	CcSEcCtD
Escitalopram—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000104	CcSEcCtD
Escitalopram—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000103	CcSEcCtD
Escitalopram—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000103	CcSEcCtD
Escitalopram—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000103	CcSEcCtD
Escitalopram—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000103	CcSEcCtD
Escitalopram—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	9.98e-05	0.000102	CcSEcCtD
Escitalopram—Confusional state—Epirubicin—peripheral nervous system neoplasm	9.91e-05	0.000102	CcSEcCtD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	9.85e-05	0.00509	CbGpPWpGaD
Escitalopram—Palpitations—Doxorubicin—peripheral nervous system neoplasm	9.85e-05	0.000101	CcSEcCtD
Escitalopram—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	9.84e-05	0.00508	CbGpPWpGaD
Escitalopram—Oedema—Epirubicin—peripheral nervous system neoplasm	9.83e-05	0.000101	CcSEcCtD
Escitalopram—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	9.83e-05	0.000101	CcSEcCtD
Escitalopram—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	9.8e-05	0.000101	CcSEcCtD
Escitalopram—Infection—Epirubicin—peripheral nervous system neoplasm	9.77e-05	0.0001	CcSEcCtD
Escitalopram—Cough—Doxorubicin—peripheral nervous system neoplasm	9.73e-05	9.99e-05	CcSEcCtD
Escitalopram—Shock—Epirubicin—peripheral nervous system neoplasm	9.67e-05	9.93e-05	CcSEcCtD
Escitalopram—Convulsion—Doxorubicin—peripheral nervous system neoplasm	9.66e-05	9.92e-05	CcSEcCtD
Escitalopram—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	9.64e-05	9.9e-05	CcSEcCtD
Escitalopram—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	9.63e-05	9.89e-05	CcSEcCtD
Escitalopram—Hypertension—Doxorubicin—peripheral nervous system neoplasm	9.62e-05	9.88e-05	CcSEcCtD
Escitalopram—Tachycardia—Epirubicin—peripheral nervous system neoplasm	9.6e-05	9.85e-05	CcSEcCtD
Escitalopram—Skin disorder—Epirubicin—peripheral nervous system neoplasm	9.55e-05	9.81e-05	CcSEcCtD
Escitalopram—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	9.51e-05	9.76e-05	CcSEcCtD
Escitalopram—Chest pain—Doxorubicin—peripheral nervous system neoplasm	9.49e-05	9.74e-05	CcSEcCtD
Escitalopram—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	9.49e-05	9.74e-05	CcSEcCtD
Escitalopram—Myalgia—Doxorubicin—peripheral nervous system neoplasm	9.49e-05	9.74e-05	CcSEcCtD
Escitalopram—Anxiety—Doxorubicin—peripheral nervous system neoplasm	9.46e-05	9.71e-05	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	9.42e-05	9.68e-05	CcSEcCtD
Escitalopram—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	9.38e-05	0.00484	CbGpPWpGaD
Escitalopram—Discomfort—Doxorubicin—peripheral nervous system neoplasm	9.38e-05	9.63e-05	CcSEcCtD
Escitalopram—Anorexia—Epirubicin—peripheral nervous system neoplasm	9.37e-05	9.62e-05	CcSEcCtD
Escitalopram—HTR2C—GPCR ligand binding—NTS—peripheral nervous system neoplasm	9.32e-05	0.00481	CbGpPWpGaD
Escitalopram—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	9.28e-05	9.53e-05	CcSEcCtD
Escitalopram—SLC6A3—NRF2 pathway—HGF—peripheral nervous system neoplasm	9.26e-05	0.00478	CbGpPWpGaD
Escitalopram—Hypotension—Epirubicin—peripheral nervous system neoplasm	9.19e-05	9.43e-05	CcSEcCtD
Escitalopram—Confusional state—Doxorubicin—peripheral nervous system neoplasm	9.17e-05	9.42e-05	CcSEcCtD
Escitalopram—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	9.1e-05	9.34e-05	CcSEcCtD
Escitalopram—Oedema—Doxorubicin—peripheral nervous system neoplasm	9.1e-05	9.34e-05	CcSEcCtD
Escitalopram—Infection—Doxorubicin—peripheral nervous system neoplasm	9.04e-05	9.28e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	8.96e-05	9.2e-05	CcSEcCtD
Escitalopram—Shock—Doxorubicin—peripheral nervous system neoplasm	8.95e-05	9.19e-05	CcSEcCtD
Escitalopram—HTR2C—GPCR ligand binding—CD55—peripheral nervous system neoplasm	8.93e-05	0.00461	CbGpPWpGaD
Escitalopram—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	8.92e-05	9.16e-05	CcSEcCtD
Escitalopram—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	8.91e-05	9.15e-05	CcSEcCtD
Escitalopram—Insomnia—Epirubicin—peripheral nervous system neoplasm	8.89e-05	9.13e-05	CcSEcCtD
Escitalopram—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	8.88e-05	9.12e-05	CcSEcCtD
Escitalopram—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	8.84e-05	9.07e-05	CcSEcCtD
Escitalopram—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	8.83e-05	9.07e-05	CcSEcCtD
Escitalopram—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	8.79e-05	9.03e-05	CcSEcCtD
Escitalopram—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	8.77e-05	9e-05	CcSEcCtD
Escitalopram—Somnolence—Epirubicin—peripheral nervous system neoplasm	8.74e-05	8.98e-05	CcSEcCtD
Escitalopram—Anorexia—Doxorubicin—peripheral nervous system neoplasm	8.67e-05	8.9e-05	CcSEcCtD
Escitalopram—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	8.65e-05	8.89e-05	CcSEcCtD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	8.6e-05	0.00444	CbGpPWpGaD
Escitalopram—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	8.55e-05	8.78e-05	CcSEcCtD
Escitalopram—Hypotension—Doxorubicin—peripheral nervous system neoplasm	8.5e-05	8.73e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	8.49e-05	8.72e-05	CcSEcCtD
Escitalopram—Fatigue—Epirubicin—peripheral nervous system neoplasm	8.48e-05	8.7e-05	CcSEcCtD
Escitalopram—Pain—Epirubicin—peripheral nervous system neoplasm	8.41e-05	8.63e-05	CcSEcCtD
Escitalopram—Constipation—Epirubicin—peripheral nervous system neoplasm	8.41e-05	8.63e-05	CcSEcCtD
Escitalopram—HTR2C—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	8.3e-05	0.00429	CbGpPWpGaD
Escitalopram—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	8.29e-05	8.51e-05	CcSEcCtD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	8.26e-05	0.00426	CbGpPWpGaD
Escitalopram—Insomnia—Doxorubicin—peripheral nervous system neoplasm	8.23e-05	8.45e-05	CcSEcCtD
Escitalopram—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	8.39e-05	CcSEcCtD
Escitalopram—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	8.11e-05	8.33e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	8.1e-05	8.32e-05	CcSEcCtD
Escitalopram—Somnolence—Doxorubicin—peripheral nervous system neoplasm	8.09e-05	8.3e-05	CcSEcCtD
Escitalopram—HRH1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	8.07e-05	0.00417	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	8.05e-05	0.00416	CbGpPWpGaD
Escitalopram—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	8.04e-05	8.26e-05	CcSEcCtD
Escitalopram—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	8.01e-05	8.22e-05	CcSEcCtD
Escitalopram—ADRA1A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	7.92e-05	0.00409	CbGpPWpGaD
Escitalopram—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	7.91e-05	8.12e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	7.85e-05	8.06e-05	CcSEcCtD
Escitalopram—Fatigue—Doxorubicin—peripheral nervous system neoplasm	7.84e-05	8.05e-05	CcSEcCtD
Escitalopram—Urticaria—Epirubicin—peripheral nervous system neoplasm	7.81e-05	8.02e-05	CcSEcCtD
Escitalopram—Pain—Doxorubicin—peripheral nervous system neoplasm	7.78e-05	7.99e-05	CcSEcCtD
Escitalopram—Constipation—Doxorubicin—peripheral nervous system neoplasm	7.78e-05	7.99e-05	CcSEcCtD
Escitalopram—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	7.77e-05	7.98e-05	CcSEcCtD
Escitalopram—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	7.77e-05	7.98e-05	CcSEcCtD
Escitalopram—HRH1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	7.74e-05	0.004	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	7.72e-05	0.00398	CbGpPWpGaD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	7.62e-05	0.00393	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	7.6e-05	0.00392	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—BCHE—peripheral nervous system neoplasm	7.55e-05	0.0039	CbGpPWpGaD
Escitalopram—CHRM1—Calcium Regulation in the Cardiac Cell—GNAS—peripheral nervous system neoplasm	7.52e-05	0.00388	CbGpPWpGaD
Escitalopram—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	7.5e-05	7.7e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	7.44e-05	7.64e-05	CcSEcCtD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	7.43e-05	0.00383	CbGpPWpGaD
Escitalopram—ADRA1A—Calcium Regulation in the Cardiac Cell—GNAS—peripheral nervous system neoplasm	7.4e-05	0.00382	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	7.32e-05	0.00378	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—TH—peripheral nervous system neoplasm	7.25e-05	0.00374	CbGpPWpGaD
Escitalopram—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	7.24e-05	7.44e-05	CcSEcCtD
Escitalopram—Urticaria—Doxorubicin—peripheral nervous system neoplasm	7.23e-05	7.42e-05	CcSEcCtD
Escitalopram—HRH1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	7.19e-05	0.00371	CbGpPWpGaD
Escitalopram—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	7.19e-05	7.38e-05	CcSEcCtD
Escitalopram—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	7.19e-05	7.38e-05	CcSEcCtD
Escitalopram—CHRM1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	7.17e-05	0.0037	CbGpPWpGaD
Escitalopram—ADRA1A—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	7.06e-05	0.00364	CbGpPWpGaD
Escitalopram—Asthenia—Epirubicin—peripheral nervous system neoplasm	7.05e-05	7.24e-05	CcSEcCtD
Escitalopram—Pruritus—Epirubicin—peripheral nervous system neoplasm	6.96e-05	7.14e-05	CcSEcCtD
Escitalopram—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	6.73e-05	6.91e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	6.7e-05	6.88e-05	CcSEcCtD
Escitalopram—Asthenia—Doxorubicin—peripheral nervous system neoplasm	6.53e-05	6.7e-05	CcSEcCtD
Escitalopram—Dizziness—Epirubicin—peripheral nervous system neoplasm	6.5e-05	6.68e-05	CcSEcCtD
Escitalopram—CHRM1—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	6.45e-05	0.00333	CbGpPWpGaD
Escitalopram—Pruritus—Doxorubicin—peripheral nervous system neoplasm	6.44e-05	6.61e-05	CcSEcCtD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	6.43e-05	0.00332	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	6.41e-05	0.00331	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	6.31e-05	0.00326	CbGpPWpGaD
Escitalopram—Vomiting—Epirubicin—peripheral nervous system neoplasm	6.25e-05	6.42e-05	CcSEcCtD
Escitalopram—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	6.22e-05	6.39e-05	CcSEcCtD
Escitalopram—Rash—Epirubicin—peripheral nervous system neoplasm	6.2e-05	6.37e-05	CcSEcCtD
Escitalopram—Dermatitis—Epirubicin—peripheral nervous system neoplasm	6.19e-05	6.36e-05	CcSEcCtD
Escitalopram—Headache—Epirubicin—peripheral nervous system neoplasm	6.16e-05	6.32e-05	CcSEcCtD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	6.04e-05	0.00312	CbGpPWpGaD
Escitalopram—Dizziness—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	6.18e-05	CcSEcCtD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	5.87e-05	0.00303	CbGpPWpGaD
Escitalopram—Nausea—Epirubicin—peripheral nervous system neoplasm	5.84e-05	6e-05	CcSEcCtD
Escitalopram—Vomiting—Doxorubicin—peripheral nervous system neoplasm	5.78e-05	5.94e-05	CcSEcCtD
Escitalopram—Rash—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	5.89e-05	CcSEcCtD
Escitalopram—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	5.73e-05	5.88e-05	CcSEcCtD
Escitalopram—Headache—Doxorubicin—peripheral nervous system neoplasm	5.7e-05	5.85e-05	CcSEcCtD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	5.5e-05	0.00284	CbGpPWpGaD
Escitalopram—Nausea—Doxorubicin—peripheral nervous system neoplasm	5.4e-05	5.55e-05	CcSEcCtD
Escitalopram—HTR2C—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	5.27e-05	0.00272	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.78e-05	0.00247	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	4.76e-05	0.00246	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	4.75e-05	0.00245	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	4.68e-05	0.00241	CbGpPWpGaD
Escitalopram—HRH1—IL-4 Signaling Pathway—AKT1—peripheral nervous system neoplasm	4.59e-05	0.00237	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.58e-05	0.00237	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	4.56e-05	0.00236	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	4.55e-05	0.00235	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	4.51e-05	0.00233	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	4.48e-05	0.00231	CbGpPWpGaD
Escitalopram—ADRA1A—AMPK Signaling—TP53—peripheral nervous system neoplasm	4.38e-05	0.00226	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4.37e-05	0.00226	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.19e-05	0.00216	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.14e-05	0.00214	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.13e-05	0.00213	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.07e-05	0.0021	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.99e-05	0.00206	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	3.97e-05	0.00205	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	3.96e-05	0.00204	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	3.91e-05	0.00202	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	3.9e-05	0.00201	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	3.9e-05	0.00201	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.87e-05	0.002	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	3.87e-05	0.002	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	3.84e-05	0.00198	CbGpPWpGaD
Escitalopram—ADRA1A—AMPK Signaling—AKT1—peripheral nervous system neoplasm	3.7e-05	0.00191	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.66e-05	0.00189	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.63e-05	0.00187	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.62e-05	0.00187	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.62e-05	0.00187	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.56e-05	0.00184	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.56e-05	0.00184	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.52e-05	0.00182	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.46e-05	0.00179	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.45e-05	0.00178	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.45e-05	0.00178	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.39e-05	0.00175	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.34e-05	0.00173	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.17e-05	0.00164	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.16e-05	0.00163	CbGpPWpGaD
Escitalopram—SLC6A4—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	3.16e-05	0.00163	CbGpPWpGaD
Escitalopram—CHRM1—Regulation of Actin Cytoskeleton—NRAS—peripheral nervous system neoplasm	3.14e-05	0.00162	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.14e-05	0.00162	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.13e-05	0.00162	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.11e-05	0.00161	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.11e-05	0.00161	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.08e-05	0.00159	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.06e-05	0.00158	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.9e-05	0.0015	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.89e-05	0.00149	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.84e-05	0.00147	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.82e-05	0.00146	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.71e-05	0.0014	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.71e-05	0.0014	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.62e-05	0.00135	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.45e-05	0.00126	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.44e-05	0.00126	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.41e-05	0.00124	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.4e-05	0.00124	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.37e-05	0.00122	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.35e-05	0.00121	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.35e-05	0.00121	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.34e-05	0.00121	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.34e-05	0.00121	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.33e-05	0.0012	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.31e-05	0.00119	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.31e-05	0.00119	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.3e-05	0.00119	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.17e-05	0.00112	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.15e-05	0.00111	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.14e-05	0.00111	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.07e-05	0.00107	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.05e-05	0.00106	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.04e-05	0.00106	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.01e-05	0.00104	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.98e-05	0.00102	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.98e-05	0.00102	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	1.89e-05	0.000977	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	1.89e-05	0.000976	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.88e-05	0.00097	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.86e-05	0.000961	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.86e-05	0.000958	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.86e-05	0.000958	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.85e-05	0.000955	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.83e-05	0.000943	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.82e-05	0.00094	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	1.81e-05	0.000936	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.79e-05	0.000926	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.79e-05	0.000923	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—HRAS—peripheral nervous system neoplasm	1.77e-05	0.000914	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.76e-05	0.000908	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	1.75e-05	0.000901	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.74e-05	0.000898	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.72e-05	0.000888	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.71e-05	0.000885	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.71e-05	0.000884	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.71e-05	0.000881	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.69e-05	0.000871	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.68e-05	0.000867	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.67e-05	0.000861	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.63e-05	0.000841	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.62e-05	0.000838	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.61e-05	0.000829	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.6e-05	0.000825	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.57e-05	0.000812	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.48e-05	0.000766	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.31e-05	0.000674	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.29e-05	0.000664	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.28e-05	0.000662	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.27e-05	0.000655	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.26e-05	0.000651	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.21e-05	0.000625	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	1.15e-05	0.000591	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.14e-05	0.000587	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.13e-05	0.000584	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.13e-05	0.000582	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.11e-05	0.000573	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.11e-05	0.000573	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.1e-05	0.000568	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.1e-05	0.000566	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.09e-05	0.000563	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.08e-05	0.000557	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.05e-05	0.000544	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.05e-05	0.000542	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.05e-05	0.000541	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.04e-05	0.000539	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.03e-05	0.000531	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	9.68e-06	0.0005	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.62e-06	0.000497	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.59e-06	0.000495	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.44e-06	0.000487	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.23e-06	0.000477	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	9.1e-06	0.00047	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	8.9e-06	0.00046	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.49e-06	0.000439	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	8.37e-06	0.000432	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	7.85e-06	0.000405	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.71e-06	0.000398	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	7.43e-06	0.000384	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	7.29e-06	0.000376	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	6.89e-06	0.000356	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	6.83e-06	0.000353	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.8e-06	0.000351	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.78e-06	0.00035	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	6.71e-06	0.000346	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.68e-06	0.000345	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.68e-06	0.000345	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.66e-06	0.000344	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.56e-06	0.000339	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.1e-06	0.000315	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	5.82e-06	0.000301	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.74e-06	0.000297	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.58e-06	0.000288	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.55e-06	0.000287	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.53e-06	0.000286	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	5.47e-06	0.000283	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.28e-06	0.000273	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.27e-06	0.000272	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.18e-06	0.000268	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.07e-06	0.000262	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.98e-06	0.000257	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.96e-06	0.000256	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.88e-06	0.000252	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.84e-06	0.00025	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.82e-06	0.000249	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.79e-06	0.000248	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.78e-06	0.000247	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.75e-06	0.000245	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.7e-06	0.000243	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.64e-06	0.000239	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	4.47e-06	0.000231	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.39e-06	0.000227	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	4.38e-06	0.000226	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.38e-06	0.000226	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.32e-06	0.000223	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.31e-06	0.000223	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.02e-06	0.000207	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.01e-06	0.000207	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.94e-06	0.000204	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.74e-06	0.000193	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.73e-06	0.000193	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.67e-06	0.00019	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.55e-06	0.000183	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.39e-06	0.000175	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.07e-06	0.000159	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.06e-06	0.000158	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.02e-06	0.000156	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3e-06	0.000155	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.94e-06	0.000152	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.93e-06	0.000151	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.89e-06	0.000149	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.6e-06	0.000134	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.59e-06	0.000134	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.55e-06	0.000132	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	2.01e-06	0.000104	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.84e-06	9.52e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.21e-06	6.23e-05	CbGpPWpGaD
